Clinical characteristics of patients with and without der(9) deletions
Covariate . | Chromosome 9 deletion (n = 33) . | Non-chromosome 9 deletion (n = 319) . | P . |
|---|---|---|---|
| Age, no. (%) | .079 | ||
| 60 y or older | 6 (18) | 109 (34) | |
| Sex | .20 | ||
| Male, no. (%) | 22 (67) | 175 (55) | |
| Albumin, g/L, median (range) | 4.1 (3.1-4.7) | 4 (2.5-5.3) | .47 |
| Bilirubin, μM/L, median (range) | 8.55 (1.71-22.23) | 8.55 (1.71-30.78) | .56 |
| Creatinine, μM, median (range) | 79.56 (53.04-123.76) | 79.56 (44.2-238.68) | .82 |
| Hemoglobin less than 12 g/L, no. (%) | 21 (64) | 145 (46) | .066 |
| Bone marrow basophils, median (range) | 2 (0-13) | 2 (0-40) | .67 |
| Bone marrow blasts 5% or greater, no. (%) | 6 (18) | 38 (12) | .28 |
| Platelets, no. (%) | .87 | ||
| 450 × 109/L to less than 700 × 109/L | 6 (18) | 53 (17) | |
| 700 × 109/L or more | 4 (12) | 33 (10) | |
| Peripheral blood basophils 7% or greater, no. (%) | 8 (24) | 55 (17) | .34 |
| Peripheral blood blasts present, no. (%) | 10 (30) | 93 (30) | .73 |
| Splenomegaly present, no. (%) | 11 (33) | 70 (22) | .19 |
| WBC 50 × 109/L, no. (%) | 8 (24) | 73 (23) | .94 |
| Ph+ at start of therapy less than 90%, no. (%) | 5 (15) | 36 (12) | .57 |
| Hepatomegaly present, no. (%) | 2 (6) | 11 (4) | .36 |
| Time from diagnosis to treatment, no. (%) | .69 | ||
| Less than 1 y | 20 (61) | 165 (52) | |
| 1-2 y | 7 (21) | 81 (25) | |
| 3 y or more | 6 (18) | 73 (23) | |
| Clonal evolution, no. (%) | 5 (15) | 36 (11) | .57 |
| Hasford risk group, no. (%) | .51 | ||
| Low | 21 (64) | 179 (57) | |
| Intermediate | 9 (27) | 115 (37) | |
| High | 3 (7) | 21 (7) | |
| Response to IFN-α therapy, no. (%) | .4 | ||
| Untreated | 20 (61) | 142 (45) | |
| Cytogenetic resistance | 7 (21) | 76 (24) | |
| Hematologic resistance | 1 (3) | 25 (8) | |
| Intolerant | 5 (15) | 75 (24) | |
| Stage, no. (%) | .20 | ||
| Chronic with prior therapy | 11 (33) | 157 (49) | |
| Chronic without prior therapy | 19 (58) | 133 (42) | |
| Accelerated | 3 (9) | 28 (9) | |
| Performance status, no. (%) | .82 | ||
| 2-4 | 10 (30) | 111 (64) | |
| Imatinib dose, no. (%) | .026 | ||
| 400 mg | 9 (27) | 151 (47) | |
| 600 mg | 5 (15) | 59 (19) | |
| 800 mg | 19 (58) | 109 (34) |
Covariate . | Chromosome 9 deletion (n = 33) . | Non-chromosome 9 deletion (n = 319) . | P . |
|---|---|---|---|
| Age, no. (%) | .079 | ||
| 60 y or older | 6 (18) | 109 (34) | |
| Sex | .20 | ||
| Male, no. (%) | 22 (67) | 175 (55) | |
| Albumin, g/L, median (range) | 4.1 (3.1-4.7) | 4 (2.5-5.3) | .47 |
| Bilirubin, μM/L, median (range) | 8.55 (1.71-22.23) | 8.55 (1.71-30.78) | .56 |
| Creatinine, μM, median (range) | 79.56 (53.04-123.76) | 79.56 (44.2-238.68) | .82 |
| Hemoglobin less than 12 g/L, no. (%) | 21 (64) | 145 (46) | .066 |
| Bone marrow basophils, median (range) | 2 (0-13) | 2 (0-40) | .67 |
| Bone marrow blasts 5% or greater, no. (%) | 6 (18) | 38 (12) | .28 |
| Platelets, no. (%) | .87 | ||
| 450 × 109/L to less than 700 × 109/L | 6 (18) | 53 (17) | |
| 700 × 109/L or more | 4 (12) | 33 (10) | |
| Peripheral blood basophils 7% or greater, no. (%) | 8 (24) | 55 (17) | .34 |
| Peripheral blood blasts present, no. (%) | 10 (30) | 93 (30) | .73 |
| Splenomegaly present, no. (%) | 11 (33) | 70 (22) | .19 |
| WBC 50 × 109/L, no. (%) | 8 (24) | 73 (23) | .94 |
| Ph+ at start of therapy less than 90%, no. (%) | 5 (15) | 36 (12) | .57 |
| Hepatomegaly present, no. (%) | 2 (6) | 11 (4) | .36 |
| Time from diagnosis to treatment, no. (%) | .69 | ||
| Less than 1 y | 20 (61) | 165 (52) | |
| 1-2 y | 7 (21) | 81 (25) | |
| 3 y or more | 6 (18) | 73 (23) | |
| Clonal evolution, no. (%) | 5 (15) | 36 (11) | .57 |
| Hasford risk group, no. (%) | .51 | ||
| Low | 21 (64) | 179 (57) | |
| Intermediate | 9 (27) | 115 (37) | |
| High | 3 (7) | 21 (7) | |
| Response to IFN-α therapy, no. (%) | .4 | ||
| Untreated | 20 (61) | 142 (45) | |
| Cytogenetic resistance | 7 (21) | 76 (24) | |
| Hematologic resistance | 1 (3) | 25 (8) | |
| Intolerant | 5 (15) | 75 (24) | |
| Stage, no. (%) | .20 | ||
| Chronic with prior therapy | 11 (33) | 157 (49) | |
| Chronic without prior therapy | 19 (58) | 133 (42) | |
| Accelerated | 3 (9) | 28 (9) | |
| Performance status, no. (%) | .82 | ||
| 2-4 | 10 (30) | 111 (64) | |
| Imatinib dose, no. (%) | .026 | ||
| 400 mg | 9 (27) | 151 (47) | |
| 600 mg | 5 (15) | 59 (19) | |
| 800 mg | 19 (58) | 109 (34) |